Adult T-cell Leukemia/Lymphoma
Adult T-cell leukemia/lymphoma (ATLL) is a rare T-cell disorder that is etiologically linked to chronic infection with human T-cell lymphotropic virus type 1. ATLL is divided into four subtypes: acute,…
Clinical Features and Current Optimal Management of Natural Killer/T-Cell Lymphoma
Extranodal natural killer/T-cell lymphoma, nasal type (ENKL), is a rare subtype of non-Hodgkin lymphoma, and its treatment outcome was previously poor. Novel treatment strategies have improved the outcomes of ENKL…
Management of Anaplastic Large Cell Lymphoma
Anaplastic large cell lymphoma (ALCL) is one of the most common peripheral T-cell lymphomas, and the incidence is higher in blacks than non-Hispanic whites. ALK-positive and ALK-negative ALCL are distinct…
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), corresponds with a heterogeneous group of mature T-cell lymphomas. Recent gene expression profiling studies have identified at least two molecular subgroups (GATA3 and…
Peripheral T-Cell Lymphoma: The Beginning of the End of the Beginning
Eric D. Jacobsen, MD, Editor The peripheral T-cell lymphomas are a group of heterogeneous mature T-cell neoplasms with disparate biology and heterogeneous clinical behavior ranging from very indolent to extremely…
Emerging Novel Therapeutic Agents in the Treatment of Patients with Gastroesophageal and Gastric Adenocarcinoma
With further understanding of the biology of gastric and gastroesophageal adenocarcinomas, strides are being made to find effective treatments through novel trial designs. This article focuses on the ongoing trials…
Barrett Esophagus and Intramucosal Esophageal Adenocarcinoma
Barrett esophagus (BE) is a precursor lesion for esophageal adenocarcinoma (EAC). Developments in imaging and molecular markers, and endoscopic eradication therapy, are available to curb the increase of EAC. Endoscopic…
Future Directions in Improving Outcomes for Patients with Gastric and Esophageal Cancer
“This issue of Hematology/Oncology Clinics of North America provides an update to the current understanding of the physiology of gastric and esophageal cancers and the state-of-the-art management of disease. Over…
Update on Gastroesophageal Adenocarcinoma Targeted Therapies
Gastroesophageal cancer (GEC) remains a major cause of cancer-related mortality worldwide. Although the incidence of distal gastric adenocarcinoma (GC) is declining in the United States, proximal esophagogastric junction adenocarcinoma (EGJ)…
Antiangiogenic Therapy in Gastroesophageal Cancer
Antiangiogenesis therapy is one of only 2 biologically targeted approaches shown to improve overall survival over standard of care in advanced adenocarcinoma of the stomach or gastroesophageal junction (GEJ). Therapeutic…
